PT -期刊文章盟Vitaliano Quaranta AU -罗莎Capozzo盟西蒙娜Arcuti AU - Silvano Dragonieri盟罗赞娜Tortelli盟——Carratu Pierluigi AU -弗朗西斯科·潘盟安娜卡萨诺AU -伊莎贝拉西蒙盟Onofrio时候伸出AU -吉安卡洛Logroscino TI -嗅鼻吸气压力(剪):经皮内窥镜Gastrostomyinpatients预后因子的肌萎缩性脊髓侧索硬化症(P1.137) DP - 2016年4月05 TA -神经病学PG - P1.137 VI - 86 IP - 16补充4099 - //www.ez-admanager.com/content/86/16_Supplement/P1.137.short 4100 - //www.ez-admanager.com/content/86/16_Supplement/P1.137.full所以Neurology2016 4月05;首页86 AB -目的探讨嗅鼻吸气压力的作用(剪)的肌萎缩性脊髓侧索硬化症(ALS)的预测因子经皮内镜胃造口术(PEG)的插入。背景与营养不良降低生存在ALS和膈弱点的这是一个重要的原因。挂钩是肠内营养的标准程序在ALS患者受损的吞咽。早期呼吸功能障碍决定了更大的能量消耗。能源需求的早期检测是重要的防止额外的肌肉损失。设计/方法回顾性研究中我们招收了139名ALS患者在2006年4月- 2012年12月。我们收集在基线人口统计学和临床数据(审查日期2014年4月)。主要结果是挂钩的。Cox回归模型。 Calibration, discrimination (C-index and continuous net reclassification improvement (cNRI) index) were assessed for all models. Results Sixty-nine patients with ALS reached the outcome during a mean follow-up of 3.6±2.1 years. Two multivariate models were estimated considering patients without missing values (n=91). The first one was a clinical-based model including: age, sex, BMI , ALSFRSr, Charlson Comorbidity Index, Forced Vital Capacity, site of onset, onset-diagnosis interval. The second model included SNIP as new predictor factor. Both models showed adequate calibration. The model including SNIP improved significantly the predictive accuracy compared with the clinical-based model (c-index: 0.800, 0.782, respectively; p=0.017). SNIP correctly classified the risk of the event within 3-years of follow-up with cNRI of 0.52 (p=0.005). Conclusions SNIP was reported as the most reliable respiratory test in ALS, combining linear decline, good sensitivity, high reproducibility both in early and in advanced stage of disease. At onset of disease, SNIP test is a predictor of early PEG insertion. Decline of respiratory functions, being an indicator of energy expenditure due to higher respiratory muscle activity, is a marker of the clinical need of establish a nutritional intake through PEG.Disclosure: Dr. QUARANTA has nothing to disclose. Dr. Capozzo has nothing to disclose. Dr. Arcuti has nothing to disclose. Dr. DRAGONIERI has nothing to disclose. Dr. Tortelli has nothing to disclose. Dr. PIERLUIGI has nothing to disclose. Dr. Panza has nothing to disclose. Dr. Cassano has nothing to disclose. Dr. Simone has received personal compensation for activities with Sanofi Aventis and Biogen. Dr. Resta has nothing to disclose. Dr. Logroscino has received personal compensation in an editorial capacity for Karger.Saturday, April 16 2016, 8:30 am-7:00 pm